Long COVID has been one of the side effects of the virus that still remains somewhat of a mystery to the medical industry. Some people have reported symptoms that range from prolonged headaches or fatigue to permanent changes to smell or taste. In a recent study, it was noted that Pfizer’s (NYSE: PFE) antiviral oral medication has been able to somewhat lower the risks of succumbing to long COVID.
Paxlovid has been provided to people who test positive for COVID-19 and are deemed to be at high risk due to other underlying medical ailments. It is not seen as a replacement for COVID vaccines from Pfizer, AstraZeneca (NASDAQ: AZN), or Moderna (NASDAQ: MRNA), but rather as a supplemental treatment for these high-risk patients.
Another company, Precision Genomics, which is a division of Ludwig Enterprises (OTC: LUDG), is developing an alternative way to potentially diagnose and treat long COVID. Using its new mRNA technology, Precision Genomics is attempting to utilize common genetic markets in each of our genomes to not only treat illnesses but predict them before they even appear. Precision Genomics is looking to find a pattern in patients that suffer from long COVID and is focusing on the presence of chronic inflammation as a common catalyst.
Featured: $PFE $MRNA $AZN $LUDG
